Alzheimer’s disease is the most prevalent form of dementia. Although it was discovered about a century ago, the first drugs applied in treatment were only introduced in therapy in the last 30 years.
This book focuses on the clinical pharmacology of drugs that aim to delay the progression of Alzheimer’s disease, such as anticholinesterases and glutamate receptor antagonists, as well as treatment for the behavioral changes caused by the progression of the disease: antidepressants, antipsychotics, anxiolytics, and mood stabilizers.
In addition, it describes important information about the pathophysiology and diagnostic methods of Alzheimer’s disease, emergency situations conditioned by the dementia process, and presents new perspectives for the treatment of Alzheimer’s disease. The ten chapters cover topics such as mechanism of action, dosage regimen, adverse reactions, drug interactions, toxicity profiles, among other information of clinical relevance. The work comprises evidence-based studies, providing a valuable resource for analyzing, prescribing and monitoring patients being treated for Alzheimer’s disease.
Written by experts with solid professional experience, this book will appeal to pharmacologists, geriatricians, neurologists, psychiatrists, biomedical clinicians, and other healthcare professionals.
5. Pharmacology of NMDA (N-methyl-D-aspartate) receptor antagonists in Alzheimer’s Disease
Carolina Witchmichen Penteado Schmidt
6. Supportive Pharmacological Treatment
Kaléu Mormino Otoni, Karla Bruna Nogueira Torres Mormino, Sandna Larissa Freitas dos Santos, Maria Liliane Luciano Pereira
7. Herbal Medicines and Supplements
Eduardo Caritá
8. Emergency Situations
Milena Carvalho Libardi, GuilhermeRiccioppo Rodrigues, Rui Kleber Martins Filho
9. Relationships between Treatment and Clinical Evaluations
Paulo Pardi, Gustavo Alves Andrade dos Santos
10. New Perspectives for Treatment in Alzheimer's Disease
Júlia Cunha Loureiro, Marcos Vasconcelos Pais, Luiz Fernando de Almeida Lima e Silva, Orestes Vicente Forlenza
Gustavo Alves Andrade dos Santos is Pharmacist-Biochemist, holds a PhD in Biotechnology, Master's degree in Pharmacy and a Post Doctorate in Anatomy and Surgery from the University of São Paulo (USP), Ribeirão Preto, São Paulo, Brazil. He also studied Neurobiology at the University of Chicago, Clinical Pharmacy at University Central of Florida, USA; Hospital Pharmacy, Necker Hospital in Paris, France, and completed a post-graduation in Hospital Pharmacy, Oswaldo Cruz Faculty, São Paulo, Brazil.
Dr. Santos is currently a Professor at the Faculty of Medicine São Leopoldo Mandic, Araras, São Paulo, Brazil and Oswaldo Cruz Faculty, São Paulo, Brazil; coordinator of the technical group of pharmaceutical care to the elderly of the Regional Pharmacy Council of the State of São Paulo. He is member of the International Society of the Alzheimer's Association to promote research and treatment of Alzheimer's disease (ISTAART) and member of the American Society of Health System Pharmacists (ASHP).
Alzheimer’s disease is the most prevalent form of dementia. Although it was discovered about a century ago, the first drugs applied in treatment were only introduced in therapy in the last 30 years.
This book focuses on the clinical pharmacology of drugs that aim to delay the progression of Alzheimer’s disease, such as anticholinesterases and glutamate receptor antagonists, as well as treatment for the behavioral changes caused by the progression of the disease: antidepressants, antipsychotics, anxiolytics, and mood stabilizers.
In addition, it describes important information about the pathophysiology and diagnostic methods of Alzheimer’s disease, emergency situations conditioned by the dementia process, and presents new perspectives for the treatment of Alzheimer’s disease. The ten chapters cover topics such as mechanism of action, dosage regimen, adverse reactions, drug interactions, toxicity profiles, among other information of clinical relevance. The work comprises evidence-based studies, providing a valuable resource for analyzing, prescribing and monitoring patients being treated for Alzheimer’s disease.
Written by experts with solid professional experience, this book will appeal to pharmacologists, geriatricians, neurologists, psychiatrists, biomedical clinicians, and other healthcare professionals.